Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy

Lung Cancer

Volumn 69, Issue 3, 2010, Pages 330-336

  Sun, Jong Mu ^a   Kim, Tae Sung ^a   Lee, Jeeyun ^a   Park, Yeon Hee ^a   Ahn, Jin Seok ^a   Kim, Hojoong ^a   Kwon, O Jung ^a   Lee, Kyung Soo ^a   Park, Keunchil ^a   Ahn, Myung Ju ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Anticoagulation; Incidence; Lung cancer; Outcomes; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS;

EID: 77955092419     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.11.015     Document Type: Article

References (32)

1. Carson J.L., Kelley M.A., Duff A., Weg J.G., Fulkerson W.J., Palevsky H.I., et al. The clinical course of pulmonary embolism. N Engl J Med 1992, 326:1240-1245.
2. Chew H.K., Davies A.M., Wun T., Harvey D., Zhou H., White R.H. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008, 6:601-608.
3. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007, 5:632-634.
4. Mousa S.A. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002, 28:45-52.
5. Francis J.L., Biggerstaff J., Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost 1998, 24:93-109.
6. Chew H.K., Wun T., Harvey D., Zhou H., White R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006, 166:458-464.
7. Stein P.D., Beemath A., Meyers F.A., Skaf E., Sanchez J., Olson R.E. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006, 119:60-68.
8. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006, 24:484-490.
9. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007, 110:2339-2346.
10. Lopez-Gomez M., Gomez-Raposo C., Lobo Samper F. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2008, 113:223-224. author reply 4.
11. Ogren M., Bergqvist D., Wahlander K., Eriksson H., Sternby N.H. Trousseau's syndrome-what is the evidence? A population-based autopsy study. Thromb Haemost 2006, 95:541-545.
12. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell C.J., Forcier R.J., et al. Rationale and experimental design for the VA Cooperative Study of Anticoagulation (Warfarin) in the treatment of cancer. Cancer 1979, 44:732-741.
13. Nash G.F., Walsh D.C., Kakkar A.K. The role of the coagulation system in tumour angiogenesis. Lancet Oncol 2001, 2:608-613.
14. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell C.J., Forcier R.J., et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981, 245:831-835.
15. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22:1944-1948.
16. Chahinian A.P., Propert K.J., Ware J.H., Zimmer B., Perry M.C., Hirsh V., et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989, 7:993-1002.
17. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005, 23:2123-2129.
18. Green D., Hull R.D., Brant R., Pineo G.F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992, 339:1476.
19. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., Levine M., Prins M.H., Buller H.R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999, 82:947-952.
20. Maurer L.H., Herndon J.E., Hollis D.R., Aisner J., Carey R.W., Skarin A.T., et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997, 15:3378-3387.
21. Smorenburg S.M., Hettiarachchi R.J., Vink R., Buller H.R. The effects of unfractionated heparin on survival in patients with malignancy-a systematic review. Thromb Haemost 1999, 82:1600-1604.
22. Winston C.B., Wechsler R.J., Salazar A.M., Kurtz A.B., Spirn P.W. Incidental pulmonary emboli detected at helical CT: effect on patient care. Radiology 1996, 201:23-27.
23. Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100:3484-3488.
24. O'Connell C.L., Boswell W.D., Duddalwar V., Caton A., Mark L.S., Vigen C., et al. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 2006, 24:4928-4932.
25. Schulman S., Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000, 342:1953-1958.
26. Gladish G.W., Choe D.H., Marom E.M., Sabloff B.S., Broemeling L.D., Munden R.F. Incidental pulmonary emboli in oncology patients: prevalence, CT evaluation, and natural history. Radiology 2006, 240:246-255.
27. Gosselin M.V., Rubin G.D., Leung A.N., Huang J., Rizk N.W. Unsuspected pulmonary embolism: prospective detection on routine helical CT scans. Radiology 1998, 208:209-215.
28. Sorensen H.T., Mellemkjaer L., Olsen J.H., Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343:1846-1850.
29. Wun T., White R.H. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 2009, 27(Suppl. 1):63-74.
30. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160:809-815.
31. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., Melton L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998, 158:585-593.
32. Lee A.Y., Levine M.N. The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost 1999, 25:137-145.